The effect of PTH(1-84) on quality of life in hypoparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2356-2361

  Cusano, Natalie E ^a   Rubin, Mishaela R ^a   McMahon, Donald J ^a   Irani, Dinaz ^a   Tulley, Amanda ^a   Sliney, James ^a   Bilezikian, John P ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CREATININE; PHOSPHATE; RECOMBINANT PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEALTH STATUS; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; HYPOPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NAUSEA; NEPHROLITHIASIS; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RAND 36 ITEM HEALTH SURVEY;

EID: 84878494366     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1239     Document Type: Article

References (27)

1. Bilezikian JP, Khan A, Potts JT Jr, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317-2337.
2. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359:391-403.
3. Cusano NE, Rubin MR, Sliney J Jr, Bilezikian JP. New therapeutic options in hypoparathyroidism. Endocrine. 2012;41:410-414.
4. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507-4514.
5. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003;88:4214-4220. (Pubitemid 37153722)
6. Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(2):391-399.
7. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26:2358-2370.
8. Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010;21:1927-1934.
9. Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab 2010;95:2680-2688.
10. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab . 2013;98:137-144.
11. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146:215-222. (Pubitemid 34162914)
12. Sikjaer T, Rolighed L, Ortenblad N, Hess A, Rejnmark L, Mosekilde L. PTH (1-84) substitution therapy in hypoparathyroidism: effects on muscle cells, muscle function, postural stability and quality of life. Program of the 34th Annual Meeting of the American Society of Bone and Mineral Research; October 12-15, 2012; Minneapolis, MN. Abstract 0141.
13. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
14. RAND Health. Medical Outcomes Study: 36-Item Short Form Survey Scoring Instructions. http://www.rand.org/health/surveys-tools/mos/mos-core-36item- scoring.html. Accessed August 20, 2012.
15. te Vaarwerk MJ, Gaal EA. Psychological distress and quality of life in drug-using and non-drug-using HIV-infected women. Eur J Public Health. 2001;11:109-115. (Pubitemid 32230051)
16. O'Brien PE, Dixon JB, Brown W, et al. The laparoscopic adjustable gastric band (Lap-Band): a prospective study of medium-term effects on weight, health and quality of life. Obes Surg. 2002;12:652-660. (Pubitemid 35305744)
17. van Baalen B, Odding E, van Woensel MP, Roebroeck ME. Reliability and sensitivity to change of measurement instruments used in a traumatic brain injury population. Clin Rehabil. 2006;20:686-700. (Pubitemid 44295106)
18. Seguin R, Lamonte M, Tinker L, et al. Sedentary behavior and physical function decline in older women: findings from the Women's Health Initiative. J Aging Res. 2012;2012:271589.
19. Gafni RI, Brahim JS, Andreopoulou P, et al. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res. 2012;27:1811-1820.
20. Rubin MR, Dempster DW, Sliney J Jr, et al. PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res . 2011;26:2727-2736.
21. Usdin TB, Gruber C, Bonner TI. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem. 1995;270:15455-15458.
22. Bagó AG, Dimitrov E, Saunders R, et al. Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience. 2009;162:128-147.
23. Balabanov S, Tollner U, Richter HP, Pohlandt F, Gaedicke G, Teller WM. Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid. Acta Endocrinol (Copenh). 1984;106:227-233. (Pubitemid 14107042)
24. Joborn C, Hetta J, Niklasson F, et al. Cerebrospinal fluid calcium, parathyroid hormone, and monoamine and purine metabolites and the blood-brain barrier function in primary hyperparathyroidism. Psychoneuroendocrinology. 1991;16:311-322.
25. Care AD, Bell NH. 1987 Evidence that parathyroid hormone crosses the blood-brain barrier. In: Cohn DV, Martin TJ, Meunier PJ, eds. Calcium regulation and bone metabolism: basic and clinical aspects: Proceedings of the 9th International Conference on Calcium Regulating Hormones and Bone Metabolism, Nice, France. October 25-November 1, 1986. New York: Elsevier; 540.
26. Sikjaer T, Rejnmark L, Rolighed L, Mosekilde L. PTH(1-84) replacement therapy in hypoparathyroidism (HypoPT): a randomized controlled trial on pharmacokinetics and dynamic effects after 24 weeks of treatment. Program of the 33rd Annual Meeting of the American Society of Bone and Mineral Research; September 16-20, 2011; San Diego, CA. Abstract 1098.
27. Fox J, Wells D, Garceau R. Relationships between pharmacokinetic profile of human PTH(1-84) and serum calcium response in postmenopausal women after 4 different methods of administration. Program of the 33rd Annual Meeting of the American Society of Bone and Mineral Research; September 16-20, 2011; San Diego. Abstract 0173.